1.
Zoli S, Pellegrini C, Casadei B, Broccoli A, Argnani L, Nanni L, et al. Prolonged complete response with lenalidomide in a relapsed diffuse large B-cell lymphoma, leg-type: a case report. Chemotherapy. 2023. Online ahead of print.
2.
Hristov AC, Tejasvi T, Wilcox RA. Cutaneous B-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(8):1326–32.
3.
Fabbri A, Cencini E, Alterini R, Rubegni P, Rigacci L, Delfino C, et al. Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas. Eur J Haematol. 2014;93(2):129–36.
4.
Swaika A, Menke DM, Jain MK, Sher T. Remission induction with lenalidomide in a patient with relapsed diffuse large B cell lymphoma of the leg type. Ann Hematol. 2015;94(5):895–6.
5.
Al Dhafiri M, Sicre de Fontbrune F, Marinho E, Deschamps L, Di-Lucca J, Crickx B, et al. Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B-cell lymphoma, leg type. Clin Case Rep. 2019;7(5):964–7.
6.
Beylot-Barry M, Mermin D, Maillard A, Bouabdallah R, Bonnet N, Duval-Modeste AB, et al. A single-arm phase II trial of lenalidomide in relapsing or refractory primary cutaneous large B-cell lymphoma, leg type. J Invest Dermatol. 2018;138(9):1982–9.
7.
Moore DC, Soni AC, Hu B, Smith ET, Levine J, Moyo TK, et al. Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type. Br J Haematol. 2022;196(4):30–3.
8.
Di Raimondo C, Abdulla FR, Zain J, Querfeld C, Rosen ST. Rituximab, lenalidomide and pembrolizumab in refractory primary cutaneous diffuse large B-cell lymphoma, leg type. Br J Haematol. 2019;187(3):79–82.
9.
Oka S, Ono K, Nohgawa M. Effective treatment with polatuzumab vedotin of relapsed and refractory primary cutaneous diffuse large B-cell lymphoma leg type. Ann Hematol. 2022;101(10):2353–4.
10.
Martinez-Høyer S, Karsan A. Mechanisms of lenalidomide sensitivity and resistance. Exp Hematol. 2020;91:22–31.
You do not currently have access to this content.